Paradigm Biopharmaceuticals (ASX:PAR) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

PAR Panoramica delle azioni

Paradigm Biopharmaceuticals Limited si occupa di ricerca e sviluppo di prodotti terapeutici per uso umano in Australia.

PAR analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	4/6
Dividendi	0/6

Premi

Analisi del rischio

Ha meno di 1 anno di pista di cassa

Realizza un fatturato inferiore a 1 milione di dollari ( A$42K )

Gli azionisti sono stati diluiti nell'ultimo anno

Non ha una capitalizzazione di mercato significativa ( A$81M )

+ 1 più rischio

Paradigm Biopharmaceuticals Limited Concorrenti

Cynata Therapeutics

ASX:CYP

AU$38.8m

Beroni Group

NSX:BTG

AU$75.9m

Noxopharm

ASX:NOX

AU$30.7m

Dimerix

ASX:DXB

AU$208.9m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Paradigm Biopharmaceuticals
Prezzi storici delle azioni
Prezzo attuale dell'azione	AU$0.20
Massimo di 52 settimane	AU$0.78
Minimo di 52 settimane	AU$0.17
Beta	0.94
1Variazione di 1 mese	-20.41%
Variazione a 3 mesi	-30.36%
Variazione di 1 anno	-67.23%
3Variazione a 3 anni	-90.53%
Variazione a 5 anni	-93.61%
Variazione dall'IPO	-47.30%

Notizie e aggiornamenti recenti

Recent updates

Paradigm Biopharmaceuticals (ASX:PAR) Is In A Strong Position To Grow Its Business

Aug 22

Here's Why We're Not At All Concerned With Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Apr 17

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Sep 21

Here's Why We're Not Too Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Jun 20

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Dec 02

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Jun 07

Is Paradigm Biopharmaceuticals Limited (ASX:PAR) Trading At A 46% Discount?

Feb 22

We're Not Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn

Jan 24

Did You Participate In Any Of Paradigm Biopharmaceuticals' (ASX:PAR) Incredible 811% Return?

Dec 28

When Will Paradigm Biopharmaceuticals Limited (ASX:PAR) Turn A Profit?

Nov 29

Rendimenti per gli azionisti

	PAR	AU Biotechs	AU Mercato
7D	-2.5%	-1.0%	1.7%
1Y	-67.2%	18.7%	17.2%

Ritorno vs Industria: PAR ha avuto una performance inferiore rispetto al Australian Biotechs che ha registrato un rendimento 17.2 % nell'ultimo anno.

Rendimento vs Mercato: PAR ha avuto una performance inferiore al mercato Australian che ha registrato un rendimento 11.2 % nell'ultimo anno.

Volatilità dei prezzi

Is PAR's price volatile compared to industry and market?
PAR volatility
PAR Average Weekly Movement	10.7%
Biotechs Industry Average Movement	10.4%
Market Average Movement	9.0%
10% most volatile stocks in AU Market	17.4%
10% least volatile stocks in AU Market	3.6%

Prezzo delle azioni stabile: Il prezzo delle azioni di PAR è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 9% ) di PAR è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2014	n/a	Paul Rennie	www.paradigmbiopharma.com

Paradigm Biopharmaceuticals Limited è impegnata nella ricerca e nello sviluppo di prodotti terapeutici per uso umano in Australia. Il suo candidato principale è Zilosul, un farmaco iniettabile a base di pentosan polisolfato di sodio per il trattamento dell'osteoartrite, della mucopolisaccaridosi, del virus Ross River, del virus Chikungunya, dell'insufficienza cardiaca cronica, delle malattie respiratorie allergiche e della sindrome da distress respiratorio acuto. La società è stata costituita nel 2014 e ha sede a Melbourne, in Australia.

Paradigm Biopharmaceuticals Limited Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Paradigm Biopharmaceuticals con la sua capitalizzazione di mercato?
PAR statistiche fondamentali
Capitalizzazione di mercato	AU$68.32m
Guadagni(TTM)	-AU$58.65m
Ricavi(TTM)	n/a

0.0x

Rapporto P/S

-1.2x

Rapporto P/E

PAR è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
PAR Conto economico (TTM)
Ricavi	AU$0
Costo del fatturato	AU$8.99k
Profitto lordo	-AU$8.99k
Altre spese	AU$58.64m
Guadagni	-AU$58.65m

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-0.17
Margine lordo	0.00%
Margine di profitto netto	0.00%
Rapporto debito/patrimonio netto	0%

Come si è comportato PAR nel lungo periodo?

Vedi performance storica e confronto

PAR Panoramica delle azioni

Premi

Analisi del rischio

Paradigm Biopharmaceuticals Limited Concorrenti

ASX:CYP

AU$38.8m

NSX:BTG

AU$75.9m

ASX:NOX

AU$30.7m

ASX:DXB

AU$208.9m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 19, 2024

New minor risk - Profitability

Insufficient new directors

New minor risk - Share price stability

New minor risk - Shareholder dilution

New minor risk - Market cap size

Recent updates

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 19, 2024

New minor risk - Profitability

Insufficient new directors

New minor risk - Share price stability

New minor risk - Shareholder dilution

New minor risk - Market cap size

New minor risk - Share price stability

Paradigm Biopharmaceuticals Ltd Announces Resignation of John Gaffney as Independent Non Executive Director, Effective Immediately

Consensus EPS estimates fall from profit to AU$0.18 loss

Forecast breakeven date pushed back to 2025

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 29, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Paradigm Biopharmaceuticals (ASX:PAR) Is In A Strong Position To Grow Its Business

Founder recently bought AU$76k worth of stock

Here's Why We're Not At All Concerned With Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Paradigm Biopharmaceuticals Ltd Advises the First Safety Review Meeting of the Data Monitoring Committee (DMC) for the Pivotal Para_OA_002 Clinical Trial

Founder recently bought AU$62k worth of stock

Paradigm Biopharmaceuticals Limited Announces Executive Changes

Price target increased to AU$2.20

Paradigm Biopharmaceuticals Limited Announces an Abstract on Paradigm's Phase 2 Clinical Trial Evaluating Injectable Pentosan Polysulfate Sodium

Paradigm Biopharmaceuticals Limited Announces First UK Subject Randomised and Dosed for the Pivotal Phase 3 Trial for the Treatment of Pain Associated with Knee OA

Paradigm Biopharmaceuticals Ltd Announces Successful Primary Endpoint in Phase 2 Trial

Paradigm Biopharmaceuticals Ltd Provides an Update on the Ongoing Multi-Centre Double-Blind Randomised Phase 2 Study Comparing PPS to Placebo in Mucopolysaccharidosis Type VI (MPS-VI) Patients

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 18, 2022

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Paradigm Biopharmaceuticals Limited Appoints Abby Macnish as Interim Company Secretary

Paradigm Biopharmaceuticals Ltd Announces MPS Clinical Program Update and Paradigm to Present At the International Conference on Lysosomal Diseases

Paradigm Biopharmaceuticals Limited Reports Important Global Progress for the Para_Oa_002 Phase 3 Clinical Trial Evaluating Zilosul® for Osteoarthritis

Paradigm Biopharmaceuticals Limited Announces PARA_OA_008 Study Evaluating Zilosul® Mechanism and Disease Modifying Effects Completes Recruitment

Forecast to breakeven in 2024

Here's Why We're Not Too Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Paradigm Biopharmaceuticals Limited Announces Chief Executive Officer Changes

Paradigm Biopharmaceuticals Limited Doses First US Subjects Under Phase 3 Trial

Price target decreased to AU$2.64

U.S. Food and Drug Administration Grants Fast Track Designation for Paradigm Biopharmaceuticals Ltd of Phase 3 Program

Founder & Non-Executive Chairman recently bought AU$51k worth of stock

Price target increased to AU$4.49

Consensus forecasts updated

No longer forecast to breakeven

Paradigm Biopharmaceuticals Limited Announces First Subjects Randomised and Dosed in Para_0A_002 Phase 3 Study in Australia

Paradigm Biopharmaceuticals Ltd Reports Postive Topline Results in Heart Failure Model

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Paradigm Biopharmaceuticals Limited Reports Preliminary Results from Phase 2 Mps I Study

Paradigm Biopharmaceuticals Limited Announces First MPS-VI Patient Dosed Under Phase 2 Trial in Brazil Investigating PPS for the Treatment of MPS-VI

Paradigm Biopharmaceuticals Limited Receives Feedback from US FDA on IND Submission

Paradigm Biopharmaceuticals Limited Announces Australian Ethics Approval for Paradigm's ARA_OA_002 Pivotal Phase 3 Clinical Trial in Participants with Knee OA

Paradigm Biopharmaceuticals Limited Makes Progress with Investigational New Drug Application

Consensus EPS estimates increase to -AU$0.15

Paradigm Biopharmaceuticals Limited Receives Key Regulatory Approvals for MPS VI Study

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Paradigm Biopharmaceuticals Ltd Receives First Revenue Through Physician Prescription of Zilosul to Patients Via the TGA SAS

Paradigm Biopharmaceuticals Ltd Provides an Update on its IND Application to the Us Food and Drug Administration

Paradigm Biopharmaceuticals Limited Updates Phase 2A, Randomised, Double-Blind, Placebo- Controlled Study

Analysts lower EPS estimates to -AU$0.17

New 90-day low: AU$2.28

Is Paradigm Biopharmaceuticals Limited (ASX:PAR) Trading At A 46% Discount?

Paradigm Biopharmaceuticals Ltd Announces It Has Received Ethics Approval for Its Phase 2 Clinical Trial to Evaluate the Treatment Effects of Pentosan Polysulfate Sodium

Paradigm Biopharmaceuticals Limited Appoints Helen Fisher as Non-Executive Director and Chair of the Audit and Risk Committee

Paradigm Biopharmaceuticals Ltd Reports Ongoing Data Update on Patients Who Received Zilosul Under the Therapeutic Goods Administration (TGA) Special Access Scheme